Latest Insights

Eli Lilly Acquires Scorpion Therapeutics' Oncology Program for $2.5 Billion

Eli Lilly announced the acquisition of Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program for up to $2.5 billion, expanding its oncology pipeline with STX-478, a differentiated PI3Kα inhibitor currently in Phase …

Continue ›››

Vevo Therapeutics Plans to Open Source 100M Single-Cell Atlas for Drug Discovery

Vevo Therapeutics has announced plans to open source its Tahoe-100M dataset, described as the world's largest single-cell transcriptomic atlas of drug impacts on patient cells. Developed in collaboration with NVIDIA's …

Continue ›››

Bioptimus Reaches $76M Milestone as It Prepares for Next-Gen AI Foundation Model

Bioptimus, a French AI startup, has announced a $76 million funding milestone, with $41 million secured in its latest round led by Cathay Innovation less than 12 months from its …

Continue ›››

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera has announced an expansion of its collaboration with AbbVie to include the development of T-cell engagers (TCEs) for oncology, leveraging AbCellera’s T-cell Engager platform.

Continue ›››

AbbVie Partners with Simcere on T-Cell Engager for Multiple Myeloma in $1B Deal

AbbVie has partnered with Simcere Zaiming, a subsidiary of Simcere Pharmaceutical, to advance a trispecific antibody candidate, SIM0500, for relapsed or refractory multiple myeloma—a blood cancer that arises from malignant …

Continue ›››

Truveta Raises $320M to Sequence 10M Exomes and Build Largest Genetic Database

The health data company Truveta, in collaboration with Regeneron and Illumina, and 17 major U.S. health systems, has launched the Truveta Genome Project. The initiative aims to sequence the exomes …

Continue ›››

Gilead Strikes $1.7B Deal with LEO Pharma for Oral STAT6 Therapies in Inflammatory Diseases

Gilead Sciences has announced a $1.7 billion collaboration with LEO Pharma, expanding its portfolio beyond infectious diseases and into inflammatory conditions. The partnership focuses on developing oral STAT6 small-molecule inhibitors …

Continue ›››

Bayer's Cell Therapy for Replacing Dopamine Neurons in Parkinson’s Advances to Phase III

Bayer, through its subsidiary BlueRock Therapeutics, has announced plans to advance bemdaneprocel (BRT-DA01), its investigational pluripotent stem cell-derived dopaminergic neuron therapy for Parkinson’s disease, into a registrational Phase III clinical trial. …

Continue ›››

Eli Lilly Acquires Scorpion Therapeutics' Oncology Program for $2.5 Billion

Vevo Therapeutics Plans to Open Source 100M Single-Cell Atlas for Drug Discovery

Bioptimus Reaches $76M Milestone as It Prepares for Next-Gen AI Foundation Model

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbbVie Partners with Simcere on T-Cell Engager for Multiple Myeloma in $1B Deal

Truveta Raises $320M to Sequence 10M Exomes and Build Largest Genetic Database

Gilead Strikes $1.7B Deal with LEO Pharma for Oral STAT6 Therapies in Inflammatory Diseases

Bayer's Cell Therapy for Replacing Dopamine Neurons in Parkinson’s Advances to Phase III

Merck Partners with Atropos Health to Accelerate Real-World Evidence Generation

Sana Reports Promising Results for Type 1 Diabetes Islet Cell Transplants Without Immunosuppression

Verdiva Bio Launches With $411M to Propel Weekly-Dosed GLP-1 Obesity Drug

Insilico Medicine Licenses Second AI-Generated Cancer Drug Candidate in a $550M Deal